BYSIBeyondspringBYSI info
$2.21info-0.23%24h
Global rank22066
Market cap$86.02M
Change 7d-
YTD Performance154.02%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Beyondspring (BYSI) Stock Overview

    BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

    BYSI Stock Information

    Symbol
    BYSI
    Address
    28 Liberty StreetNew York, NY 10005United States
    Founded
    -
    Trading hours
    -
    Website
    https://beyondspringpharma.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    646 305 6387

    Beyondspring (BYSI) Price Chart

    -
    Value:-

    Beyondspring Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $2.21
    N/A
    Market Cap
    $86.02M
    N/A
    Shares Outstanding
    38.92M
    N/A
    Employees
    73.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org